BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
54.49
+1.17 (2.19%)
Jun 3, 2026, 3:40 PM EDT - Market open
BioMarin Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,242 | 3,221 | 2,854 | 2,419 | 2,096 | 1,846 | |
Revenue Growth (YoY) | 9.90% | 12.87% | 17.97% | 15.42% | 13.53% | -0.76% |
Cost of Revenue | 760.88 | 717.44 | 580.24 | 532.06 | 503.02 | 470.52 |
Gross Profit | 2,481 | 2,504 | 2,274 | 1,887 | 1,593 | 1,376 |
Selling, General & Admin | 1,205 | 1,153 | 1,009 | 892.41 | 823.24 | 759.38 |
Depreciation & Amortization Expenses | 19.02 | 19.39 | 43.26 | 62.21 | 67.19 | 69.93 |
Research & Development | 942 | 921.93 | 747.18 | 746.77 | 649.61 | 628.79 |
Other Operating Expenses | - | - | -10 | - | -108 | - |
Total Operating Expenses | 2,166 | 2,094 | 1,789 | 1,701 | 1,432 | 1,458 |
Operating Income | 315.23 | 409.48 | 484.21 | 185.77 | 160.97 | -82.34 |
Interest Income | 78.45 | 74.9 | 74.88 | 58.34 | 18.03 | 10.48 |
Interest Expense | -22.99 | -10.9 | -12.67 | -17.34 | -15.97 | -15.34 |
Other Non-Operating Income (Expense) | 14.91 | 9 | -4.67 | -38.22 | -13.46 | 11.85 |
Total Non-Operating Income (Expense) | 70.37 | 73 | 57.55 | 2.79 | -11.4 | 6.99 |
Pretax Income | 385.59 | 482.48 | 541.76 | 188.56 | 149.58 | -75.35 |
Provision for Income Taxes | 116.85 | 133.58 | 114.9 | 20.92 | 8.02 | -11.27 |
Net Income | 268.74 | 348.9 | 426.86 | 167.65 | 141.56 | -64.08 |
Net Income to Common | 268.74 | 348.9 | 426.86 | 167.65 | 141.56 | -64.08 |
Net Income Growth | -48.70% | -18.26% | 154.62% | 18.43% | - | - |
Shares Outstanding (Basic) | 192 | 192 | 190 | 188 | 185 | 183 |
Shares Outstanding (Diluted) | 195 | 197 | 197 | 192 | 189 | 183 |
Shares Change (YoY) | -1.48% | 0.35% | 2.67% | 1.39% | 3.34% | -4.61% |
EPS (Basic) | 1.40 | 1.82 | 2.25 | 0.89 | 0.76 | -0.35 |
EPS (Diluted) | 1.37 | 1.80 | 2.21 | 0.87 | 0.75 | -0.35 |
EPS Growth | -49.07% | -18.55% | 154.02% | 16.00% | - | - |
Shares Outstanding | 193.27 | 192.3 | 190.76 | 188.6 | 186.25 | 183.91 |
Free Cash Flow | 767.06 | 724.96 | 487.42 | 62.57 | 54.94 | 208.96 |
Free Cash Flow Growth | 5.81% | 48.73% | 679.02% | 13.88% | -73.71% | - |
Free Cash Flow Per Share | 3.94 | 3.67 | 2.48 | 0.33 | 0.29 | 1.14 |
Gross Margin | 76.53% | 77.73% | 79.67% | 78.01% | 76.00% | 74.52% |
Operating Margin | 9.72% | 12.71% | 16.97% | 7.68% | 7.68% | -4.46% |
Profit Margin | 8.29% | 10.83% | 14.96% | 6.93% | 6.75% | -3.47% |
FCF Margin | 23.66% | 22.51% | 17.08% | 2.59% | 2.62% | 11.32% |
EBITDA | 389.12 | 489.04 | 580.64 | 290.16 | 262.94 | 25.7 |
EBITDA Margin | 12.00% | 15.18% | 20.35% | 11.99% | 12.54% | 1.39% |
EBIT | 315.23 | 409.48 | 484.21 | 185.77 | 160.97 | -82.34 |
EBIT Margin | 9.72% | 12.71% | 16.97% | 7.68% | 7.68% | -4.46% |
Effective Tax Rate | 30.30% | 27.69% | 21.21% | 11.09% | 5.36% | 14.96% |